JP Morgan Keeps Underweight Rating on SLR Investment (SLRC)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2025
0mins
Should l Buy SLRC?
Source: NASDAQ.COM
JP Morgan's Recommendation: On October 1, 2025, JP Morgan maintained an Underweight recommendation for SLR Investment (NasdaqGS:SLRC), with an average one-year price target of $17.24/share, indicating a potential upside of 14.28% from its closing price of $15.09/share.
Fund Sentiment and Ownership Changes: There are 138 funds reporting positions in SLR Investment, with a 10.40% increase in ownership over the last quarter. Notable changes include Thornburg Investment Management maintaining its shares, while Jpmorgan Chase and Aristotle Capital Boston reduced their holdings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLRC
Wall Street analysts forecast SLRC stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 14.450
Low
16.50
Averages
17.44
High
19.00
Current: 14.450
Low
16.50
Averages
17.44
High
19.00
About SLRC
SLR Investment Corp. is a closed-end, externally managed, non-diversified management investment company. It invests primarily in privately held United States middle-market companies. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. It directly and indirectly invests primarily in leveraged middle market companies in the form of senior secured loans, financing leases and unsecured loans, and equity securities. In addition, it shall invest in foreign markets, including emerging markets. Its business is focused primarily on the direct origination of investments through portfolio companies or their financial sponsors. It invests in various industries, such as financial services, multi-sector holdings, health care providers and services, health care equipment and supplies, pharmaceuticals, consumer services, capital markets, media, software, and asset management. Its investment manager is SLR Capital Partners, LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Insider Buying Activity in SLRC and ELV
- SLRC Insider Purchase: Michael S. Gross acquired 104,819 shares of SLRC on Wednesday at $14.74 each, totaling an investment of $1.55 million, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Price Comparison: On Friday, SLRC shares traded as low as $14.34, which is 2.7% below Gross's purchase price, reflecting short-term market volatility that may influence investor buying decisions.
- ELV Insider Purchase: Elevance Health's Director Steven H. Collis bought 3,000 shares on Thursday at $289.84 each, totaling $869,520, signaling executive optimism regarding the company's prospects.
- ELV Market Price Dynamics: On Friday, ELV shares traded as low as $281.50, which is 2.9% lower than Collis's purchase price, indicating market reactions that could affect other investors' confidence.
See More
SLR Investment (SLRC) Q4 2025 Earnings Transcript
See More
SLR Investment Reports Mixed Q4 Results with Dividend Declaration
- Stable Net Investment Income: SLR Investment reported net investment income of $0.40 per share in Q4, aligning with consensus estimates, yet remaining below the $0.41 quarterly dividend level, indicating challenges in sustaining earnings.
- Investment Income Performance: The total investment income reached $54.5 million, trailing the consensus by $0.51 million, suggesting that revenue growth faces pressure in the current economic environment, which may impact future dividend payments.
- Slight Increase in Net Asset Value: As of December 31, 2025, the net asset value stood at $18.26 per share, reflecting a modest increase from the previous year and the third quarter of 2025, indicating stability in asset quality.
- Strong Portfolio Performance: At year-end, SLR Investment had only about 2% exposure to software companies, and payment-in-kind income represented just 2% of total investment income in Q4, demonstrating effective risk management in the portfolio.
See More
SLR Investment Reports Q4 2025 Earnings Results
- Earnings Performance: SLR Investment reported a GAAP EPS of $0.40 for Q4 2025, aligning with market expectations, indicating stability in the company's profitability.
- Investment Income Decline: Total investment income was $54.46 million, down 2.0% year-over-year, missing expectations by $0.51 million, reflecting some pressure on the company's revenue generation capabilities.
- Net Asset Value Changes: As of December 31, 2025, SLR's NAV per share was $18.26, showing a modest increase from both September 30, 2025, and December 31, 2024, indicating resilience in asset management.
- Market Outlook Analysis: Despite a resilient portfolio, analysts suggest that SLR Investment is not yet a buy, reflecting a cautious market sentiment regarding its future growth prospects.
See More
SLR Investment to Announce Q4 Earnings on February 24
- Earnings Announcement Date: SLR Investment is set to release its Q4 earnings report on February 24 after market close, drawing significant investor attention that could influence market sentiment.
- Earnings Expectations: The consensus EPS estimate stands at $0.40, indicating a cautious outlook on the company's profitability, despite a slight decline compared to the previous year.
- Revenue Projections: The consensus revenue estimate is $54.97 million, reflecting a 1.1% year-over-year decrease, which raises concerns about SLR Investment's revenue growth potential in the current economic climate.
- Revision Trends: Over the last three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a lack of confidence among analysts regarding the company's future performance, which may impact stock price movements.
See More
Latest Wall Street Rating Updates
- BofA Downgrades Qualcomm: Bank of America has downgraded Qualcomm from neutral to underperform with a price target of $145, citing lukewarm projected sales and EPS growth of only 2% and 1% CAGR from 2025 to 2028, significantly lagging the semiconductor sector's expected 17% growth.
- Deutsche Bank Upgrades Teladoc: Deutsche Bank upgraded Teladoc from hold to buy, highlighting an attractive risk/reward profile due to compelling valuation and a deliverable strategy for its BetterHelp business, indicating a strong potential for future growth.
- TD Cowen Upgrades Rivian: TD Cowen upgraded Rivian from hold to buy, projecting full-scale demand for its R2 model to reach between 212,000 and 335,000 units, suggesting significant upside potential against 2027 consensus estimates.
- Morgan Stanley Reiterates Microsoft Overweight: Morgan Stanley reiterated its overweight rating on Microsoft, emphasizing the readiness of its Office product suite for the upcoming Agentic AI offerings, with general availability expected on May 1, 2026, priced at $99 per user per month.
See More
Insider Buying Activity in SLRC and ELV
- SLRC Insider Purchase: Michael S. Gross acquired 104,819 shares of SLRC on Wednesday at $14.74 each, totaling an investment of $1.55 million, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Price Comparison: On Friday, SLRC shares traded as low as $14.34, which is 2.7% below Gross's purchase price, reflecting short-term market volatility that may influence investor buying decisions.
- ELV Insider Purchase: Elevance Health's Director Steven H. Collis bought 3,000 shares on Thursday at $289.84 each, totaling $869,520, signaling executive optimism regarding the company's prospects.
- ELV Market Price Dynamics: On Friday, ELV shares traded as low as $281.50, which is 2.9% lower than Collis's purchase price, indicating market reactions that could affect other investors' confidence.
See More
SLR Investment (SLRC) Q4 2025 Earnings Transcript
See More
SLR Investment Reports Mixed Q4 Results with Dividend Declaration
- Stable Net Investment Income: SLR Investment reported net investment income of $0.40 per share in Q4, aligning with consensus estimates, yet remaining below the $0.41 quarterly dividend level, indicating challenges in sustaining earnings.
- Investment Income Performance: The total investment income reached $54.5 million, trailing the consensus by $0.51 million, suggesting that revenue growth faces pressure in the current economic environment, which may impact future dividend payments.
- Slight Increase in Net Asset Value: As of December 31, 2025, the net asset value stood at $18.26 per share, reflecting a modest increase from the previous year and the third quarter of 2025, indicating stability in asset quality.
- Strong Portfolio Performance: At year-end, SLR Investment had only about 2% exposure to software companies, and payment-in-kind income represented just 2% of total investment income in Q4, demonstrating effective risk management in the portfolio.
See More
SLR Investment Reports Q4 2025 Earnings Results
- Earnings Performance: SLR Investment reported a GAAP EPS of $0.40 for Q4 2025, aligning with market expectations, indicating stability in the company's profitability.
- Investment Income Decline: Total investment income was $54.46 million, down 2.0% year-over-year, missing expectations by $0.51 million, reflecting some pressure on the company's revenue generation capabilities.
- Net Asset Value Changes: As of December 31, 2025, SLR's NAV per share was $18.26, showing a modest increase from both September 30, 2025, and December 31, 2024, indicating resilience in asset management.
- Market Outlook Analysis: Despite a resilient portfolio, analysts suggest that SLR Investment is not yet a buy, reflecting a cautious market sentiment regarding its future growth prospects.
See More
SLR Investment to Announce Q4 Earnings on February 24
- Earnings Announcement Date: SLR Investment is set to release its Q4 earnings report on February 24 after market close, drawing significant investor attention that could influence market sentiment.
- Earnings Expectations: The consensus EPS estimate stands at $0.40, indicating a cautious outlook on the company's profitability, despite a slight decline compared to the previous year.
- Revenue Projections: The consensus revenue estimate is $54.97 million, reflecting a 1.1% year-over-year decrease, which raises concerns about SLR Investment's revenue growth potential in the current economic climate.
- Revision Trends: Over the last three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a lack of confidence among analysts regarding the company's future performance, which may impact stock price movements.
See More
